Skip to main content
Livermore
Livermore
ZHEN

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of AMLX: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders1191110−8
Shares43.6M2.67M43.5M+2.49M (+6.1%)
Value$82.9M$5.07M$140.8M+$62.9M (+80.8%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to AMLX in Q3 2024
InstitutionSharesValue% of portfolio
TCG Crossover Management, LLC4,643,812$15.0M1.27%
BlackRock, Inc.2,548,206$8.26M0.00%
Perceptive Advisors LLC2,125,649$6.89M0.15%
Nantahala Capital Management, LLC1,404,564$4.55M0.38%
Falcon Edge Capital, LP669,487$2.17M0.67%
Ghost Tree Capital, LLC325,000$1.05M0.36%
Marshall Wace, LLP283,986$920.1K0.00%
Shay Capital LLC117,328$380.1K0.11%
Jefferies Financial Group Inc.46,200$149.7K0.00%
Marex Group plc40,000$129.6K0.00%
Bank of New York Mellon Corp23,679$76.7K0.00%
Premier Path Wealth Partners, LLC20,265$65.7K0.01%
Prudential Financial Inc19,400$62.9K0.00%
Aries Wealth Management15,000$48.6K0.01%
Corton Capital Inc.13,104$42.5K0.02%
Bayesian Capital Management, LP10,700$34.7K0.00%
Bank of Nova Scotia10,696$34.7K0.00%
Atria Wealth Solutions, Inc.10,000$32.4K0.00%
nVerses Capital, LLC2,100$6.80K0.00%
Oliver Lagore Vanvalin Investment Group1,600$5.18K0.00%
Dunhill Financial, LLC600$1.94K0.00%
Advisor Group Holdings, Inc.215$6960.00%
Point72 Asset Management, L.P.200$6480.00%

Sold out (31)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of AMLX in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Boxer Capital, LLC1,500,000$2.85M
Woodline Partners LP523,772$995.2K
Aviva PLC363,032$689.8K
Sofinnova Investments, Inc.299,691$569.4K
Hudson Bay Capital Management LP250,000$475.0K
State of Wisconsin Investment Board138,500$263.1K
Y-Intercept (Hong Kong) Ltd118,105$224.4K
LMR Partners LLP113,300$215.3K
Alpine Global Management, LLC108,862$206.8K
Maven Securities LTD100,000$190.0K
Centiva Capital, LP90,733$172.4K
Alps Advisors Inc90,357$171.7K
Engineers Gate Manager LP84,044$159.7K
Paloma Partners Management Co57,954$110.1K
Sphera Funds Management Ltd.36,050$68.5K
Cerity Partners LLC33,365$63.4K
Allspring Global Investments Holdings, LLC28,785$54.7K
Rhumbline Advisers28,779$54.7K
Mirae Asset Global ETFs Holdings Ltd.26,032$49.5K
Point72 (DIFC) Ltd25,953$49.3K
Zuckerman Investment Group, LLC20,000$38.0K
Jump Financial, LLC17,685$33.6K
ProShare Advisors LLC11,000$20.9K
Teza Capital Management LLC10,160$19.3K
Banque Cantonale Vaudoise5,900$11.0K
Macquarie Group Ltd2,528$4.80K
Caption Management, LLC1,200$2.28K
New York State Common Retirement Fund444$844
Redwood Wealth Management Group, LLC200$380
Kelly Financial Services LLC33$63
Covestor Ltd43$0

Not filed for Q3 2024 yet (1)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AMLX in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.2,669,741$5.07M